Friday, October 29, 2010

New anticancer hope with Sprycel (Dasatinib)

The U.S.FDA has approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first time diagnosed in patients. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a very slowly progressing blood and bone marrow disease linked to a genetic abnormality.
(Source: http://www.fda.gov/, for full detail click here)

No comments:

Post a Comment